Yoshida E, Sumi H, Maruyama M, Mihara H, Sakai R
Department of Physiology, Miyazaki Medical College, Japan.
Clin Chim Acta. 1987 Aug 14;167(2):155-64. doi: 10.1016/0009-8981(87)90368-8.
An enzyme-linked immunosorbent assay (ELISA) for acid-stable trypsin inhibitor was developed using goat antibodies raised against urinary trypsin inhibitor purified from normal human urine. The assay was highly sensitive and precise, and gave reproducible results in the range of 1-1,000 ng/ml. The specificity and sensitivity of this assay permitted measurement of a low content of acid stable trypsin inhibitor in different tissue extracts and body fluids. Using the new method, the mean level in plasma samples taken from healthy individuals was found to be 54.9 +/- 17.4 (mean +/- SD) micrograms/ml and that of acid-treated plasma was 11.5 +/- 3.0 micrograms/ml (n = 27). The calculated specific activity of acid stable trypsin inhibitor in acid treated plasma was 300 U/mg, while that of highly purified inhibitor is 2,100 U/mg. These results suggest the presence of both acid unstable protein having the same antigenicity as urinary trypsin inhibitor and the inactive form of acid stable trypsin inhibitor.
利用针对从正常人尿液中纯化的尿胰蛋白酶抑制剂产生的山羊抗体,开发了一种用于酸稳定胰蛋白酶抑制剂的酶联免疫吸附测定(ELISA)方法。该测定法高度灵敏且精确,在1 - 1000 ng/ml范围内可得到可重复的结果。该测定法的特异性和灵敏度使得能够测量不同组织提取物和体液中酸稳定胰蛋白酶抑制剂的低含量。使用这种新方法,发现从健康个体采集的血浆样本中的平均水平为54.9 +/- 17.4(平均值 +/- 标准差)微克/毫升,酸处理血浆的平均水平为11.5 +/- 3.0微克/毫升(n = 27)。酸处理血浆中酸稳定胰蛋白酶抑制剂的计算比活性为300 U/mg,而高度纯化抑制剂的比活性为2100 U/mg。这些结果表明存在与尿胰蛋白酶抑制剂具有相同抗原性的酸不稳定蛋白以及酸稳定胰蛋白酶抑制剂的无活性形式。